

# Fallopian Tube Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/F5883E25EFBEN.html>

Date: April 2020

Pages: 1496

Price: US\$ 2,000.00 (Single User License)

ID: F5883E25EFBEN

## Abstracts

Fallopian Tube Cancer - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2020, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 20, 72, 52, 2, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 8 and 1 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fallopian Tube Cancer

(Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Fallopian Tube Cancer - Overview

Fallopian Tube Cancer - Therapeutics Development

Fallopian Tube Cancer - Therapeutics Assessment

Fallopian Tube Cancer - Companies Involved in Therapeutics Development

Fallopian Tube Cancer - Drug Profiles

Fallopian Tube Cancer - Dormant Projects

Fallopian Tube Cancer - Discontinued Products

Fallopian Tube Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Fallopian Tube Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Fallopian Tube Cancer - Pipeline by AB Science SA, H1 2020

Fallopian Tube Cancer - Pipeline by AbbVie Inc, H1 2020

Fallopian Tube Cancer - Pipeline by ADC Therapeutics SA, H1 2020  
Fallopian Tube Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020  
Fallopian Tube Cancer - Pipeline by AiVita Biomedical Inc, H1 2020  
Fallopian Tube Cancer - Pipeline by Aldeyra Therapeutics Inc, H1 2020  
Fallopian Tube Cancer - Pipeline by Amgen Inc, H1 2020  
Fallopian Tube Cancer - Pipeline by Anew Oncology Inc, H1 2020  
Fallopian Tube Cancer - Pipeline by Apexigen Inc, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Fallopian Tube Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

AB Science SA  
AbbVie Inc  
ADC Therapeutics SA  
Advenchen Laboratories LLC  
AiVita Biomedical Inc  
Aldeyra Therapeutics Inc  
Amgen Inc  
Anew Oncology Inc  
Apexigen Inc  
Apollomics Inc  
Apotex Inc  
Aravive Inc  
Arrien Pharmaceuticals LLC  
Astellas Pharma Inc  
Astex Pharmaceuticals Inc  
AstraZeneca Plc  
Atara Biotherapeutics Inc  
Basilea Pharmaceutica Ltd  
Bayer AG  
BeiGene Ltd  
Bio-Path Holdings Inc



BioIntegrator Ltd  
Boehringer Ingelheim International GmbH  
Boston Biomedical Inc  
Bristol-Myers Squibb Co  
Celldex Therapeutics Inc  
Celsion Corp  
Celyad SA  
Chipscreen Biosciences Ltd  
Clovis Oncology Inc  
Corcept Therapeutics Inc  
Cotinga Pharmaceuticals Inc  
Cristal Therapeutics BV  
EirGenix Inc  
Eisai Co Ltd  
Eli Lilly and Co  
Ellipses Pharma Ltd  
ENB Therapeutics LLC  
Esperance Pharmaceuticals Inc  
Exelixis Inc  
F. Hoffmann-La Roche Ltd  
Fujifilm Holdings Corp  
Gene Techno Science Co Ltd  
Genentech Inc  
Genmab AS  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
Gradalis Inc  
I-Mab Biopharma Co Ltd  
ImmunityBio Inc  
ImmunoGen Inc  
IMPACT Therapeutics Inc  
IMV Inc  
Incyte Corp  
Innate Pharma SA  
Innovent Biologics Inc  
InSight Biopharmaceuticals Ltd  
Jiangsu Hengrui Medicine Co Ltd  
Johnson & Johnson  
Juno Therapeutics Inc

Karyopharm Therapeutics Inc  
Kazia Therapeutics Ltd  
Kyowa Kirin Co Ltd  
Leap Therapeutics Inc  
Lokon Pharma AB  
MabVax Therapeutics Holdings Inc  
Mateon Therapeutics Inc  
MaxCyte Inc  
Merck & Co Inc  
Merck KGaA  
Mersana Therapeutics Inc  
Millennium Pharmaceuticals Inc  
Moderna Inc  
Mycenax Biotech Inc  
Neon Therapeutics Inc  
Northlake International LLC  
Novartis AG  
NuCana Plc  
Oasmia Pharmaceutical AB  
OBI Pharma Inc  
Omnitura Therapeutics Inc  
Oncoinvent AS  
Oncolix Inc  
Oncologie Inc  
Oncolytics Biotech Inc  
OncoQuest Inc  
Oncovir Inc  
Ono Pharmaceutical Co Ltd  
Pfizer Inc  
Pharma Mar SA  
PharmAbcine Inc  
Plexxikon Inc  
Prestige BioPharma Pte Ltd  
PsiOxus Therapeutics Ltd  
PTC Therapeutics Inc  
R-Pharm US LLC  
Regeneron Pharmaceuticals Inc  
Rgenix Inc  
Richter Gedeon Nyrt

Rigel Pharmaceuticals Inc  
Samyang Holdings Corp  
Sanofi  
SELLAS Life Sciences Group Inc  
Shenzen SiBiono GeneTech Co Ltd  
Sotio AS  
Sutro Biopharma Inc  
Syndax Pharmaceuticals Inc  
Synermore Biologics Co Ltd  
Taiho Pharmaceutical Co Ltd  
Tmunity Therapeutics Inc  
Transgene SA  
Vascular Biogenics Ltd  
Verastem Inc  
Vyriad Inc  
Xcovery Holding Co LLC  
Xencor Inc  
Zymeworks Inc

## I would like to order

Product name: Fallopian Tube Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/F5883E25EFBEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F5883E25EFBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970